Company description

Aurinia Pharmaceuticals Inc. (ticker symbol: AUPH) is a biopharmaceutical company that is committed to developing and commercializing innovative therapies for the treatment of various severe autoimmune diseases. The company's main focus is on the development of voclosporin, a drug that has the potential to change the treatment landscape for these debilitating conditions. Along with voclosporin, AUPH has a robust pipeline of other promising drug candidates that are in different stages of clinical development. The company prides itself on its team of experienced scientists and researchers who are dedicated to pushing the boundaries of medical science and finding breakthrough treatments for patients in need. AUPH is committed to providing patients with safe, effective, and affordable treatment options, and is continuously investing in research and development to advance their mission. With its strong portfolio of intellectual property, global partnerships, and a committed management team, AUPH is well-positioned to make a significant impact in the field of autoimmune diseases. The company's dedication to research and innovation has earned them recognition and accolades within the biotech industry, making AUPH a highly reputable and reputable company poised for success.